Stage-specific embryonic antigen-4 is a histological marker reflecting the malignant behavior of prostate cancer.
Aged
Apoptosis
Biomarkers, Tumor
/ metabolism
Biopsy
Glycosphingolipids
/ metabolism
Humans
Lymph Nodes
/ metabolism
Lymphatic Metastasis
Lymphocytes, Tumor-Infiltrating
/ metabolism
Male
Middle Aged
Multivariate Analysis
Neoplasm Grading
Neoplasm Invasiveness
Neoplasm Staging
Prognosis
Prostatectomy
Prostatic Neoplasms
/ diagnosis
Stage-Specific Embryonic Antigens
/ metabolism
Survival Analysis
Apoptosis · prostate cancer
Biochemical recurrence
SSEA-4
Tumor-infiltrating immune cells
Journal
Glycoconjugate journal
ISSN: 1573-4986
Titre abrégé: Glycoconj J
Pays: United States
ID NLM: 8603310
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
02
03
2019
accepted:
20
06
2019
revised:
15
05
2019
pubmed:
28
6
2019
medline:
13
2
2020
entrez:
28
6
2019
Statut:
ppublish
Résumé
Stage-specific embryonic antigen-4 (SSEA-4), a specific marker for pluripotent stem cells, plays an important role in the malignant behavior of several cancers. Here, SSEA-4 expression was evaluated by immunohistochemistry using monoclonal antibody RM1 specific to SSEA-4 in 181 and 117 prostate cancer (PC) specimens obtained by biopsy and radical prostatectomy (RP), respectively. The relationships between SSEA-4 expression in cancer cells or the presence of SSEA-4-positive tumor-infiltrating immune cells (TICs) and clinicopathological parameters were analyzed. SSEA-4 expression in cancer cells was significantly associated with Gleason score, local progression, and lymph node and distant metastasis. In RP specimens, high SSEA-4 expression in cancer cells and the presence of SSEA-4-positive TICs were significant predictors of pT3, i.e., invasion and worse biochemical recurrence (BCR) after RP, respectively, in univariate analysis. In contrast, combination of high SSEA-4 expression in cancer cells and the presence of SSEA-4-positive TICs was an independent predictor for pT3 and BCR in multivariate analysis. Biologically this combination was also independently associated with suppression of apoptosis. Thus, the co-expression of SSEA-4 in cancer cells and TICs may have crucial roles in the malignant aggressiveness and prognosis of PC. Invasive potential and suppression of apoptosis may be linked to SSEA-4 expression.
Identifiants
pubmed: 31243630
doi: 10.1007/s10719-019-09882-2
pii: 10.1007/s10719-019-09882-2
pmc: PMC6744380
doi:
Substances chimiques
Biomarkers, Tumor
0
Glycosphingolipids
0
Stage-Specific Embryonic Antigens
0
stage-specific embryonic antigen-4
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
409-418Références
J Cell Mol Med. 2016 Apr;20(4):721-30
pubmed: 26849468
Oncol Lett. 2010 May;1(3):417-421
pubmed: 22966318
Glycobiology. 2015 Aug;25(8):902-17
pubmed: 25978997
Transl Res. 2016 Sep;175:116-28
pubmed: 27140699
J Biol Chem. 2015 Jun 26;290(26):16043-58
pubmed: 25940087
Oral Oncol. 2013 Aug;49(8):787-95
pubmed: 23768762
J Cancer Res Clin Oncol. 2010 May;136(5):787-93
pubmed: 19946707
Sci Rep. 2016 Jan 20;6:16993
pubmed: 26787499
FEBS Lett. 2002 Oct 30;531(1):93-8
pubmed: 12401210
J Cancer Res Clin Oncol. 2017 Nov;143(11):2393-2400
pubmed: 28823006
J Immunol. 2009 Oct 15;183(8):5050-8
pubmed: 19801523
Clin Genitourin Cancer. 2019 Feb;17(1):e221-e226
pubmed: 30472041
Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):2482-7
pubmed: 24550271
Proc Natl Acad Sci U S A. 2013 Feb 12;110(7):2517-22
pubmed: 23355685
Int J Cancer. 2009 Nov 15;125(10):2323-31
pubmed: 19598259
Sci Rep. 2015 Apr 08;5:9604
pubmed: 25853231
J Biol Chem. 1994 Feb 25;269(8):5644-52
pubmed: 7509790
Urology. 2005 Jun;65(6):1238-43
pubmed: 15922418
Breast Cancer Res. 2015 Nov 25;17(1):146
pubmed: 26607327
Nat Commun. 2011 Jan 18;2:162
pubmed: 21245843
Prostate. 2019 Feb;79(3):320-330
pubmed: 30488530
J Biol Chem. 2003 Jul 18;278(29):26474-9
pubmed: 12716912
Nature. 2001 Nov 1;414(6859):105-11
pubmed: 11689955
Eur Respir J. 2013 Mar;41(3):656-63
pubmed: 22743677
EMBO J. 1983;2(12):2355-61
pubmed: 6141938
Oncotarget. 2017 Nov 6;9(63):32238-32249
pubmed: 30181813
Anticancer Res. 2007 Nov-Dec;27(6C):4345-50
pubmed: 18214042
Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):40-5
pubmed: 20018687